BCRX BioCryst Pharmaceuticals, Inc.
$7.30
BioCryst Pharmaceuticals, Inc. (BCRX) Earnings News
Earnings press releases, previews and reviews for BioCryst Pharmaceuticals, Inc. (BCRX), newest first. Our most recent is review: BioCryst Beats on ORLADEYO Strength, but a One-Time Pharmacy Inventory Build Explains Why Product Guidance Stayed Put.
Wednesday
November 4, 2026
1:17 PM ET
BioCryst Beats on ORLADEYO Strength, but a One-Time Pharmacy Inventory Build Explains Why Product Guidance Stayed Put
Earnings Whispers · Review
Wednesday
November 4, 2026
7:00 AM ET
BioCryst Reports Third Quarter 2026 Financial Results
Tuesday
October 27, 2026
12:59 PM ET
BioCryst Must Prove Orladeo Can Carry the Load Without a License Windfall
Earnings Whispers · Preview
Wednesday
October 21, 2026
4:01 PM ET
BioCryst to Report Third Quarter 2026 Financial Results on November 4
Wednesday
August 5, 2026
7:00 AM ET
BioCryst Reports Second Quarter 2026 Financial Results
Wednesday
July 22, 2026
7:00 AM ET
BioCryst to Report Second Quarter 2026 Financial Results on August 5
Monday
June 29, 2026
7:00 AM ET
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility